TFF PHARMACEUTICALS, INC. (TFFP) News
Filter TFFP News Items
TFFP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TFFP News Highlights
- For TFFP, its 30 day story count is now at 4.
- Over the past 6 days, the trend for TFFP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, DRUG and AE are the most mentioned tickers in articles about TFFP.
Latest TFFP News From Around the Web
Below are the latest news stories about TFF PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TFFP as an investment opportunity.
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACTreatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute r |
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TACCompany to host conference call and webcast on Tuesday, December 19th at 8:30 am ETFORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and |
TFF Pharmaceuticals Announces Reverse Stock SplitCommon Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. T |
TFF Pharmaceuticals Appoints Thomas B. King to Board of DirectorsFORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceu |
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of DirectorsFORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. “I am pleased to welcome Dr. Patane to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Ph |
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of DirectorsFORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Catherine Lee, J.D. has been appointed to its Board of Directors. “We are pleased to announce the appointment of Catherine Lee to our Board of Directors,” said Harlan Weisman, M.D., Chief Executive Officer |
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that company management will be participating in the 2023 Benchmark Discovery One-on-One Investor Conference being held December 7, 2023 at the New York Athletic Club in New York City. The company has two produc |
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Call TranscriptTFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded. I will now turn the call over to our host, Corey Davis of LifeSci […] |
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateCompany remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm ET to provide overview of expected data readouts from ongoing Phase 2 studies FORT WORTH, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patente |
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film FreezingResearch shows the Company’s Thin Film Freezing can reformulate broad range of monoclonal antibodies in combination with Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System for intranasal deliveryFORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announ |